Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

Relationships and Activities. The Council of Experts was supported by AstraZeneca.

Bibliographic Details
Published in:	Российский кардиологический журнал
Main Authors:	S. N. Tereshchenko, M. V. Shestakova, F. T. Ageev, G. R. Galstyan, A. S. Galyavich, M. G. Glezer, I. V. Zhirov, Yu. A. Karpov, Zh. D. Kobalava, S. T. Matskeplishvili
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-06-01
Subjects:	heart failure with reduced ejection fraction dapa-hf trial dapagliflozin
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3919

Internet